Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.85

€0.85

-1.840%
-0.016
-1.840%
€1.60

€1.60

 
27.03.24 / Frankfurt WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Latest predictions
€1.60
25.07.23
-24.10%
buy
Your prediction

Cerenis Therapeutics Holding S.A. Stock

We can see a decrease in the price for Cerenis Therapeutics Holding S.A.. Compared to yesterday it has lost -€0.016 (-1.840%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Cerenis Therapeutics Holding S.A. stock is not clear.
With a target price of 1 € there is a slightly positive potential of 17.1% for Cerenis Therapeutics Holding S.A. compared to the current price of 0.85 €.
Our community identified positive and negative aspects for Cerenis Therapeutics Holding S.A. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Cerenis Therapeutics Holding S.A. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cerenis Therapeutics Holding S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cerenis Therapeutics Holding S.A. -1.840% -3.867% -25.641% -60.183% -29.383% -16.185% 123.077%
Sensorion SA -8.700% 2.941% -16.494% 160.940% 101.250% -64.537% -
Genoway S.A. Inh. 8.510% -4.326% -1.571% -0.922% -14.739% 3.014% 60.000%
Hybrigenics S.A. -1.370% -2.667% -19.780% -86.015% -61.376% -97.788% -93.540%

News

ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112


Access here the full press release



ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies

ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D


ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant

ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week": https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"


ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant